StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
TTRXTurn Therapeutics Inc.
stockpulse.co.kr
Nasdaq
$10.30▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $306.8MShares out 29.8M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

11
  • 5d agoAfter-hours26.10.20 05:15
    ARSOther#●●●#●●●

    Turn Therapeutics Inc.

    Turn Therapeutics Inc. has filed its Annual Report to Security Holders (ARS) for the fiscal year ended December 31, 2025. This filing provides comprehensive information regarding the company's financial condition and business operations for the reporting period.…more

    $10.30+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 5d agoAfter-hours26.10.20 05:05
    DEF 14AOther

    Turn Therapeutics Inc.

    Turn Therapeutics Inc. will hold its annual meeting of stockholders virtually on November 30, 2026. The meeting will address the election of directors and the ratification of the independent accounting firm, with 30,532,704 shares of common stock outstanding as of the record date of October 5, 2026.…more

    $10.30+0.00%vs prev close
    View filingShare
  • 10.7Pre-market26.10.07 08:30filed
    8-KKey event

    Turn Therapeutics Inc.

    Turn Therapeutics released an updated investor presentation on October 6, 2026, detailing the clinical development progress of its lead pipeline candidate, GX-03. The company expects to report topline results from its Phase 2 trial for GX-03 in atopic dermatitis in Q1 2027, alongside planned clinical milestones for onychomycosis and hidradenitis suppurativa.…more

    $10.30+0.00%vs prev close
    View filingShare

10 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 8.20Pre-market26.08.20 21:06
    #●●●

    Turn Therapeutics Publishes Peer-Reviewed Research on GX-03

    Turn Therapeutics released research showing that its GX-03 candidate significantly reduced key inflammatory and itch-inducing cytokines in an in-vivo study. The company has yet to provide a clear timeline for clinical trials or commercialization.…more

    $10.30+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga